Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.
about
Current and emerging azole antifungal agentsAntifungal agents for common paediatric infectionsSimultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindololComparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusionBioanalytical data in decision making: discovery and development.Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria.Effects of cytochrome p450 inhibitors on itraconazole and fluconazole induced cytotoxicity in hepatocytes.Chemogenomic profiling predicts antifungal synergies.Administration of fluconazole in children below 1 year of age.Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients.Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model.Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.Metabolism-based drug interactions involving oral azole antifungals in humans.Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.Tinea capitis.Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.Fluconazole susceptibilities of bloodstream Candida sp. isolates as determined by National Committee for Clinical Laboratory Standards method M27-A and two other methodsSafety and tolerability of fluconazole in children.Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephrInteraction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.Sensitive bioassay for determination of fluconazole concentrations in plasma using a Candida albicans mutant hypersusceptible to azoles.Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.Rationale for combination antifungal therapy.Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomesTreatment of acute cryptococcal disease.Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testingHepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation.Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazoleFluconazole penetration in cerebral parenchyma in humans at steady statePharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infectionAvian cryptococcosis.Antifungal therapy: from amphotericin B to present.Fungal skin infections.Treatment of cutaneous candidiasis through fluconazole encapsulated cubosomes.Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropeniaHuman subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques.Sequential antibiotic therapy: Effective cost management and patient care.Fluconazole for the treatment of candidiasis: 15 years experience.Successful treatment of brainstem blastomycosis with fluconazole
P2860
Q24550733-53D59B8F-C6FE-4D5F-916D-E9DC1887AA4AQ24656835-AC7116AF-D94C-40AE-8C7C-BA2CE6949F9FQ28367555-DC21F3C2-F168-429B-AF29-ADCE66247063Q30311996-DE166836-B41D-49A9-939E-F7DDB2C16D12Q30874557-8B3E3DD4-CE24-4803-B385-A8B922B35E28Q33202199-5FE9902C-C222-4451-9E1B-7ACA2283FE3FQ33601260-CE95BB50-3FFA-48F0-B233-64BBF4AF6FF2Q33668319-7E3DDBDE-B481-48EF-AB71-97DF0B4C66CFQ33680336-203EA757-9420-4D8E-88AC-89E79408D055Q33689354-655EC5B8-385A-4083-B7A0-57C8209B6AA3Q33693370-00E26A63-5428-4AF0-A2CB-EDD15DA8E1C1Q33695281-C8F694A3-E734-41FC-8A6B-450239EE60D2Q33719828-AF1D2547-BAB1-4711-8201-3152B59831A8Q33722115-64F3B427-B033-4DB8-B786-CEBA5D9F3DAFQ33894467-1F641FF4-9AA3-4DF8-BA16-F4BD08F915AEQ33916883-796033F4-5504-4F2B-A0A4-80DDE30DFA78Q33938082-8F029296-0156-4D0A-AD40-D338399420EAQ33961413-F6761E68-5E09-442A-9837-0BB6D7E06B83Q33977410-4433CFB5-222E-4029-B439-C93C0D9F8438Q33978188-8007C6CB-3309-481C-A51C-77263817DC95Q33978197-7B90723C-6764-4D20-9C86-244FEA00F9F5Q33981566-3EBDF8E8-B1E6-46E7-A929-1BE909E29E8FQ34335230-F0B467E9-04F3-4C68-AD52-CBEDE2678093Q34335236-08F5F1F3-8B2F-4AB8-9612-C96373F0C30BQ34359090-7021CA10-00F2-4E84-A85B-394EEBE32FBFQ34390201-7CB3DCFB-A43B-40A2-AEBE-9F513E5E1242Q34647337-862DBB3F-C00C-4AE9-B192-1E9F051286BFQ34980027-0E0D8BEB-7857-430F-8C7C-72B00CF4CED0Q35112281-18593EF3-BF39-45CF-A9B9-532752742085Q35114601-915AC460-9BB2-43DE-B2E1-00DE86CA5522Q35117518-729F8964-4410-4DB8-8017-C7B4E3E3A07CQ35215635-01501708-857E-4C02-AF7A-1F98237C007CQ35245371-AD779B63-44F2-434C-9C95-48541CDCF745Q35448106-1EDA0BDA-2C44-448D-8610-0CD722CB3C62Q35580829-04A0EE6A-BCEC-4CB2-9F23-B18DE41FC843Q35589175-C3B1DC34-4C2A-4E3E-A629-E1B3EBCE8CCCQ35825795-3E557078-2F14-4085-AFAB-A7EE098B9069Q35893020-5010B08D-FDEF-4E58-AFDD-25D950EED481Q35917407-0F62EC88-2AB1-4012-9811-B2F22EFDC941Q35970727-145F7252-841B-4294-89C2-4C5B617D5702
P2860
Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Fluconazole. A review of its p ...... erficial and systemic mycoses.
@en
Fluconazole. A review of its p ...... erficial and systemic mycoses.
@nl
type
label
Fluconazole. A review of its p ...... erficial and systemic mycoses.
@en
Fluconazole. A review of its p ...... erficial and systemic mycoses.
@nl
prefLabel
Fluconazole. A review of its p ...... erficial and systemic mycoses.
@en
Fluconazole. A review of its p ...... erficial and systemic mycoses.
@nl
P1433
P1476
Fluconazole. A review of its p ...... erficial and systemic mycoses.
@en
P2093
P304
P356
10.2165/00003495-199039060-00006
P577
1990-06-01T00:00:00Z
P6179
1040540338